Claudin-6 mediates an embryonic stem cell-driven antitumor response against breast cancer
Summary: Stem cells are emerging sources of antigens for cancer immunotherapy. Here, we used TNG-A mouse embryonic stem cells to trigger an anticancer response against tumors derived from E0771 mouse breast cancer cells, possibly mediated by the mouse immune system. TNG-A cells were cultured in the...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004225009496 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Summary: Stem cells are emerging sources of antigens for cancer immunotherapy. Here, we used TNG-A mouse embryonic stem cells to trigger an anticancer response against tumors derived from E0771 mouse breast cancer cells, possibly mediated by the mouse immune system. TNG-A cells were cultured in the presence or absence of two specific kinase inhibitors. While the inhibitors preserved TNG-A pluripotency, their removal altered the morphology, transcriptome, and proteome of TNG-A cells, increasing their similarities with E0771 cancer cells. Double pre-exposure by subcutaneous injection of TNG-A cells followed by E0771 implantation drastically decreased E0771-derived tumor size in mice. Serum cytokine quantifications suggested a transient immune reaction associated with tumor regression. Nevertheless, pre-exposure to TNG-A cells impaired for the tight junction protein Claudin 6 failed to decrease tumor size. Our findings demonstrate the anti-tumor effects of embryonic stem cells and anticipate their potential as an allogenic source for cancer immunotherapy. |
|---|---|
| ISSN: | 2589-0042 |